ARCA Biopharma Equity 2024

ARCA Biopharma Aktienanalyse

What does ARCA Biopharma do?

ARCA Biopharma Inc. is a biopharmaceutical company specializing in the development of therapies for cardiovascular diseases. The company was founded in 2004 and is headquartered in Westminster, Colorado, USA. ARCA Biopharma develops novel drugs tailored to the needs of patients with cardiovascular diseases. The history of ARCA Biopharma began when the company acquired exclusive rights to a technology for identifying genetic mutations associated with increased susceptibility to cardiovascular diseases. Thanks to this technology, ARCA Biopharma was able to develop more targeted, effective therapies based on the patient's genetic makeup. ARCA Biopharma's business model is based on the development of therapeutic technologies for cardiovascular diseases. The company utilizes its expertise in genomic research to develop customized, innovative drug therapies that are more targeted to the patient's genetic needs. ARCA Biopharma conducts intensive research and development work to develop significantly more effective drugs that are aimed at revolutionizing the market. ARCA Biopharma offers various types of medical therapies tailored to the needs of patients with cardiovascular diseases. The company focuses on RNA drug development and genomic research. RNA drugs are a relatively new type of medical therapy based on the regulation of gene expression. The company has several products in various stages of development tailored to the needs of patients with cardiovascular diseases. One of ARCA Biopharma's most successful products is Gencaro, a novel drug used in the treatment of heart failure. Gencaro is a beta-blocker specifically designed for patients with genetic markers associated with increased susceptibility to cardiovascular diseases. ARCA Biopharma has received multiple awards and numerous accolades for its innovation and research work. The company has partnerships with leading research and development organizations around the world to maximize its research efforts and accelerate the development of new innovative drugs. Overall, ARCA Biopharma aims to improve the lives of patients with cardiovascular diseases by providing tailored therapies that meet the genetic needs of the patient. The company has gained a reputation for its innovative research work and the development of highly effective drugs, and will undoubtedly play a leading role in the future development of therapies for cardiovascular diseases. ARCA Biopharma ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing ARCA Biopharma's Equity

ARCA Biopharma's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding ARCA Biopharma's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating ARCA Biopharma's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

ARCA Biopharma's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in ARCA Biopharma’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about ARCA Biopharma Stock

What is the equity of ARCA Biopharma this year?

ARCA Biopharma has equity of 37.02 M USD this year.

What was the equity of ARCA Biopharma compared to the previous year?

The equity of ARCA Biopharma has increased/decreased by -11.17% decreased compared to the previous year.

What impact does a high equity have on investors of ARCA Biopharma?

A high equity is advantageous for investors of ARCA Biopharma as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of ARCA Biopharma?

A low equity can be a risk for investors of ARCA Biopharma, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of ARCA Biopharma affect the company?

An increase in equity of ARCA Biopharma can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of ARCA Biopharma affect the company?

A reduction in equity of ARCA Biopharma can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of ARCA Biopharma?

Some factors that can affect the equity of ARCA Biopharma include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of ARCA Biopharma so important for investors?

The equity of ARCA Biopharma is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can ARCA Biopharma take to change the equity?

To change equity, ARCA Biopharma can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does ARCA Biopharma pay?

Over the past 12 months, ARCA Biopharma paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, ARCA Biopharma is expected to pay a dividend of 0 USD.

What is the dividend yield of ARCA Biopharma?

The current dividend yield of ARCA Biopharma is .

When does ARCA Biopharma pay dividends?

ARCA Biopharma pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of ARCA Biopharma?

ARCA Biopharma paid dividends every year for the past 0 years.

What is the dividend of ARCA Biopharma?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is ARCA Biopharma located?

ARCA Biopharma is assigned to the 'Health' sector.

Wann musste ich die Aktien von ARCA Biopharma kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of ARCA Biopharma from 5/23/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 5/23/2024.

When did ARCA Biopharma pay the last dividend?

The last dividend was paid out on 5/23/2024.

What was the dividend of ARCA Biopharma in the year 2023?

In the year 2023, ARCA Biopharma distributed 0 USD as dividends.

In which currency does ARCA Biopharma pay out the dividend?

The dividends of ARCA Biopharma are distributed in USD.